Cargando…

JWA loss promotes cell migration and cytoskeletal rearrangement by affecting HER2 expression and identifies a high-risk subgroup of HER2-positive gastric carcinoma patients

BACKGROUND AND AIMS: JWA, a microtubule-associated protein (MAP) involved in apoptosis, has been identified as a suppressor of metastasis, and it affects cell migration in melanoma and its downregulation in tumor is an idependent negative prognostic factor in resectable gastric cancer. HER2 overexpr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Qian, Jing, Zhu, Weiyou, Wang, Keming, Ma, Lin, Xu, Jin, Xu, Tongpeng, Røe, Oluf Dimitri, Li, Aiping, Zhou, Jianwei, Shu, Yongqian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2016
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5095045/ https://www.ncbi.nlm.nih.gov/pubmed/27167206 http://dx.doi.org/10.18632/oncotarget.9211

Ejemplares similares

JWA down-regulates HER2 expression via c-Cbl and induces lapatinib resistance in human gastric cancer cells
por: Ma, Ling, et al.
Publicado: (2016)

JAC1 suppresses proliferation of breast cancer through the JWA/p38/SMURF1/HER2 signaling
por: Ren, Yanlin, et al.
Publicado: (2021)

Synergistic Role between p53 and JWA: Prognostic and Predictive Biomarkers in Gastric Cancer
por: Liu, Xin, et al.
Publicado: (2012)

Astrocytic JWA deletion exacerbates dopaminergic neurodegeneration by decreasing glutamate transporters in mice
por: Wang, Rihua, et al.
Publicado: (2018)

Targeting JWA for Cancer Therapy: Functions, Mechanisms and Drug Discovery
por: Ding, Kun, et al.
Publicado: (2022)

JWA reverses cisplatin resistance via the CK2—XRCC1 pathway in human gastric cancer cells
por: Xu, W, et al.
Publicado: (2014)

JWA deficiency induces malignant transformation of murine embryonic fibroblast cells
por: Qi, Hong, et al.
Publicado: (2018)

Anti-PD-1 plus anti-angiogenesis combined with chemotherapy in patients with HER2-negative advanced or metastatic gastric cancer: a multi-institutional retrospective study
por: Xu, Tongpeng, et al.
Publicado: (2023)

JWA suppresses the invasion of human breast carcinoma cells by downregulating the expression of CXCR4
por: Xu, Lingyun, et al.
Publicado: (2018)

JAC4 Protects from X-ray Radiation-Induced Intestinal Injury by JWA-Mediated Anti-Oxidation/Inflammation Signaling
por: Zhou, Yan, et al.
Publicado: (2022)

HER kinase inhibition in patients with HER2- and HER3-mutant cancers
por: Hyman, David M., et al.
Publicado: (2018)

EGCG regulates the cross-talk between JWA and topoisomerase IIα in non-small-cell lung cancer (NSCLC) cells
por: Li, Yuan, et al.
Publicado: (2015)

JAC1 targets YY1 mediated JWA/p38 MAPK signaling to inhibit proliferation and induce apoptosis in TNBC
por: Zhai, Zurong, et al.
Publicado: (2022)

Loss of HER2 Positivity after Trastuzumab in HER2-Positive Gastric Cancer: Is Change in HER2 Status Significantly Frequent?
por: Ishimine, Yu, et al.
Publicado: (2015)

Zenocutuzumab, a HER2xHER3 Bispecific Antibody, Is Effective Therapy for Tumors Driven by NRG1 Gene Rearrangements
por: Schram, Alison M., et al.
Publicado: (2022)

HER2 heterogeneity is a poor prognosticator for HER2-positive gastric cancer
por: Kaito, Akio, et al.
Publicado: (2019)

JWA Deficiency Suppresses Dimethylbenz[a]Anthracene-Phorbol Ester Induced Skin Papillomas via Inactivation of MAPK Pathway in Mice
por: Gong, Zhenghua, et al.
Publicado: (2012)

The role of HER2 and HER3 in HER2-amplified cancers beyond breast cancers
por: Majumder, Avisek, et al.
Publicado: (2021)

Antitumor activity of pan‐HER inhibitors in HER2‐positive gastric cancer
por: Yoshioka, Takahiro, et al.
Publicado: (2018)

JWA regulates XRCC1 and functions as a novel base excision repair protein in oxidative-stress-induced DNA single-strand breaks
por: Wang, Shouyu, et al.
Publicado: (2009)

HER2-enriched subtype and novel molecular subgroups drive aromatase inhibitor resistance and an increased risk of relapse in early ER+/HER2+ breast cancer
por: Bergamino, Milana A., et al.
Publicado: (2022)

HER2-positive gastric cancer identified by serum HER2: A case report
por: SAITO, MAYUKO, et al.
Publicado: (2016)

HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer
por: Van Cutsem, Eric, et al.
Publicado: (2014)

HER2-positive gastric cancer
por: Boku, Narikazu
Publicado: (2013)

JWA suppresses proliferation in trastuzumab-resistant breast cancer by downregulating CDK12
por: Liang, Yan, et al.
Publicado: (2021)

Cytogenetic analysis of HER1/EGFR, HER2, HER3 and HER4 in 278 breast cancer patients
por: Sassen, Andrea, et al.
Publicado: (2008)

HER3, p95HER2, and HER2 protein expression levels define multiple subtypes of HER2-positive metastatic breast cancer
por: Lipton, Allan, et al.
Publicado: (2013)

Comparison of tumors with HER2 overexpression versus HER2 amplification in HER2-positive breast cancer patients
por: Horimoto, Yoshiya, et al.
Publicado: (2022)

Targeting HER2-positive gastric cancer with a novel (18)F-labeled Z(HER2:342) probe
por: Pan, Yunyun, et al.
Publicado: (2019)

Optimal Duration of Neoadjuvant Taxane and Carboplatin Combined With Anti-HER2 Targeted Therapy for HER2-Positive Breast Cancer
por: Xie, Yifan, et al.
Publicado: (2021)

Preclinical HER-2 Vaccines: From Rodent to Human HER-2
por: Lollini, Pier-Luigi, et al.
Publicado: (2013)

HER2 signaling regulates HER2 localization and membrane retention
por: Jeong, Jaekwang, et al.
Publicado: (2017)

Correlation of HER2, p95HER2 and HER3 Expression and Treatment Outcome of Lapatinib plus Capecitabine in her2-Positive Metastatic Breast Cancer
por: Han, Sae-Won, et al.
Publicado: (2012)

HER2 somatic mutations are associated with poor survival in HER2‐negative breast cancers
por: Wang, Tonghui, et al.
Publicado: (2017)

Assessment of HER2 testing patterns, HER2+ disease, and the utilization of HER2-directed therapy in early breast cancer
por: Stenehjem, David D, et al.
Publicado: (2014)

HER-3 expression in HER-2-amplified breast carcinoma
por: Czopek, Jacek, et al.
Publicado: (2013)

Novel HER2-Directed Treatments in Advanced Gastric Carcinoma: AnotHER Paradigm Shift?
por: Ricci, Angela Dalia, et al.
Publicado: (2021)

Pan‐HER inhibitors overcome lorlatinib resistance caused by NRG1/HER3 activation in ALK ‐rearranged lung cancer
por: Taniguchi, Hirokazu, et al.
Publicado: (2022)

JWA regulates TRAIL-induced apoptosis via MARCH8-mediated DR4 ubiquitination in cisplatin-resistant gastric cancer cells
por: Wang, Q, et al.
Publicado: (2017)

Model-Based Analysis of HER Activation in Cells Co-Expressing EGFR, HER2 and HER3
por: Shankaran, Harish, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_78dhlnu73mbbrao1i79pq0hvev